CASR and colonic neoplasm: Use of histone deacetylase inhibitors in colon cancer cell lines most of which poorly express CaSR has implicated the involvement of H3K9 deacetylation in the silencing of CASR in colorectal cancer (Hizaki et al., 2011; Fetahu et al., 2014a).